KLRK1 and triple-negative breast carcinoma: NKG2D has been employed in CAR-T therapy for various hematologic malignancies, such as acute myeloid leukemia (AML) [49] and MM [27]) as well as solid tumors (including colorectal cancer [50] and triple-negative breast cancer [26].